— but some will reward investors by launching on the stock market or being acquired by a bigger drug company.
The company also licenses out research technology and is building an in-house startup incubator, giving it a mix of stable revenue and more speculative sales. It's that mix of internal and external revenue streams that makes CEO Errik Anderson confident in the valuation. An Alloy Therapeutics employee works in one of the company's labs.Just a couple of seasoned hub-and-spoke biotechs have actually made it to the finish line: launching a commercial drug.
"My gut is that you should have your core programs in place and have clinical stage assets before raising hundreds of millions of dollars," she said. After all, gluttony is still one of the seven deadly sins. Atlas Venture partner Bruce Booth put it bluntly during aHow an MIT economist helped create mega biotechs
To further balance the scales, BridgeBio is also developing cancer therapies that could be used on more than 500,000 patients. BridgeBio